quality of bioequivalence studies
Download
Skip this Video
Download Presentation
Quality of Bioequivalence Studies

Loading in 2 Seconds...

play fullscreen
1 / 16

Quality of Bioequivalence Studies - PowerPoint PPT Presentation


  • 148 Views
  • Uploaded on

Quality of Bioequivalence Studies. Evaluation of Quality and Interchangeability of Medicinal Products 5 – 9 November 2007 Jiaxing, China Dr. Henrike Potthast; Temporary Advisor to WHO. Quality of Bioequivalence Studies. e.g. acc. to Directive 2001/20/EC:

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Quality of Bioequivalence Studies' - yves


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
quality of bioequivalence studies

Quality of Bioequivalence Studies

Evaluation of Quality and Interchangeability of Medicinal Products

5 – 9 November 2007

Jiaxing, China

Dr. Henrike Potthast; Temporary Advisor to WHO

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies2
Quality of Bioequivalence Studies
  • e.g. acc. to Directive 2001/20/EC:

“The verification of compliance with the standards of good clinical practice and the need to subject data, information and documents to inspection in order to confirm that they have been properly generated, recorded and reported are essential in order to justify the involvement of human subjects in clinical trials.”

  • GCP & GLP
  • finding/definition of inspection triggers

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies3
Quality of Bioequivalence Studies
  • General Requirements

 BE studies as a substitute for clinical and preclinical data

 Quality of the BE study is of decisive importance for approval of the product

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies4
Quality of Bioequivalence Studies
  • Environmental triggers - examples

 random selection acc. to annual inspection program

 information from other regulatory authorities

  • type of product (e.g. particular narrow therap. range)
  • lack of previous inspections for product/applicant/location
  • ……
  • general indication for inspection

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies5
Quality of Bioequivalence Studies
  • Early phase triggers - examples

 history of (serious) problems for sponsor, CRO, sites, labs

  • involvement of clinical site/CRO/labs in many studies
  • business related issues (e.g. bankruptcy, mergers)
  • lack of audit certificates
  • …..
  • Still general indication without direct implication of trial data

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies6
Quality of Bioequivalence Studies
  • Evaluation phase triggers - examples

 protocol gives incomplete/illogical information

  • numerous protocol violations
  • unsatisfactory explanation for protocol violations
  • data too clean/too messy
  • number of missing values/drop outs/nds….
  • Findings due to knowledge from literature and other studies; type of generic product already known

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies7
Quality of Bioequivalence Studies
  • Evaluation phase triggers – contd.

 conflicting (PK-)results as compared to known data

  • insufficient documentation (clinic, analytics, statistics)
  • missing documentation
  • implausibility/inconsistency of clinical or analytical data

(e.g. long half-life – short wash-out – no carry-over?!)

  • doubtful statistics or change in the analysis….

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies8
Quality of Bioequivalence Studies
  • Information exchange
  • evaluation of triggers

positive

(negative – non serious/’formal’)

negative – serious  request/list of questions

 e.g. EMEA inspection data base since 2004

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies9
Quality of Bioequivalence Studies
  • Evaluation/Inspection based on source data/raw data

e.g.

  • print-outs of chromatograms

 signed CRFs

 analytic protocols

  • time schedules
  • list of providers …….

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies10
Quality of Bioequivalence Studies

Data verification & QA issues

  • GCP compliance statement available?
  • audit/monitoring reports available?
  • protocol valid, i.e. signed (incl. amendments)?
  • was the protocol followed?
  • genuine study subjects/volunteers?
  • archiving of source/raw data?
  • violations of the protocol justified? ….

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies11
Quality of Bioequivalence Studies

Data verification & QA issues ctd.

  • excluded subjects - traceable?
  • consistent trial results?
  • final responsibility of investigators (signing)?
  • source of investigative products?
  • batch information available?
  • handling of investigative products?

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies12
Quality of Bioequivalence Studies

Data verification & QA issues ctd.

  • validation of bioanalytical method?
    • timing
    • validation characteristics
    • adherence to GLP
    • SOPs available……
  • calibrated equipment?
  • computer systems????
  • archiving of bioanalytical raw data

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies13
Quality of Bioequivalence Studies

Data verification & QA issues ctd.

  • statistical plan adhered to?
    • transfer of analytical data to statistics
    • main pharmacokinetic characteristics
    • method of determination
    • nd values considered?
  • statistical outcome and conclusions consistent?
  • archiving of statistical raw data

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies14
Quality of Bioequivalence Studies

Regulatory & ethical issues

  • independent ethics committee?
  • ethical approval based on appropriate documentation?
    • protocol
    • amendments
    • investigators brochure; SPC
    • subjects information informed consent
  • approval of competent authority in time?
  • subjects from vulnerable populations?
  • signing of subjects available?

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies15
Quality of Bioequivalence Studies

Regulatory & ethical issues ctd.

  • insurance of subjects adequate?
  • adequately instructed personnel?
    • investigators
    • technicians
    • suppliers…..
  • safety evaluation assured throughout the trial?
  • retention samples sufficient?
  • storage of retention samples?

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

quality of bioequivalence studies16
Quality of Bioequivalence Studies

THANK YOU FOR YOUR ATTENTION

The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health

ad